Journal
NEUROPHARMACOLOGY
Volume 62, Issue 3, Pages 1544-1553Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2010.12.001
Keywords
Acetylcholine; Cognition; Schizophrenia; Attention; Cortex; Translational research
Categories
Funding
- NIH [MH080332, MH080426, MH086530, MH086701]
- NSF [0726285]
- Division Of Behavioral and Cognitive Sci
- Direct For Social, Behav & Economic Scie [0726285] Funding Source: National Science Foundation
Ask authors/readers for more resources
Effective treatment of the cognitive symptoms of schizophrenia has remained an elusive goal. Despite the intense focus on treatments acting at or via cholinergic mechanisms, little remains known about the dynamic cholinergic abnormalities that contribute to the manifestation of the cognitive symptoms in patients. Evidence from basic neuroscientific and psychopharmacological investigations assists in proposing detailed cholinergic mechanisms and treatment targets for enhancement of attentional performance. Dynamic, cognitive performance-dependent abnormalities in cholinergic activity have been observed in animal models of the disorder and serve to further refine such proposals. Finally, the potential usefulness of individual groups of cholinergic drugs and important issues concerning the interactions between pro-cholinergic and antipsychotic treatments are addressed. The limited evidence available from patient studies and animal models indicates pressing research needs in order to guide the development of cholinergic treatments of the cognitive symptoms of schizophrenia. This article is part of a Special Issue entitled 'Schizophrenia'. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available